{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:36:22Z","timestamp":1775820982901,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.clinthera.2021.04.009","type":"journal-article","created":{"date-parts":[[2021,5,30]],"date-time":"2021-05-30T18:18:24Z","timestamp":1622398704000},"page":"e209-e216","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of Prescribing Practices and Outcomes Using Direct-acting Oral Anticoagulants After Cardiac Surgery"],"prefix":"10.1016","volume":"43","author":[{"given":"Dareen M.","family":"Kanaan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan M.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhynn","family":"Malloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.04.009_bib0001","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"NEJM"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0002","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"NEJM"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0003","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"NEJM"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0004","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"NEJM"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0005","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"NEJM"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0006","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"NEJM"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0007","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Agnelli","year":"2010","journal-title":"NEJM"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0008","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Buller","year":"2013","journal-title":"NEJM"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0009","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S2352-3026(16)00023-5","article-title":"Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the HOKUSAI-VTE study","volume":"3","author":"Raskob","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0010","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"NEJM"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0011","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"NEJM"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0012","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"NEJM"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0013","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Eng J Med"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0014","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"NEJM"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0015","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/j.clinthera.2019.10.008","article-title":"Clinical benefit of direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valves","volume":"41","author":"Russo","year":"2019","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0016","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.4022\/jafib.1456","article-title":"Safety of the direct acting oral anticoagulant edoxaban for atrial fibrillation after cardiac surgery: pilot study","volume":"9","author":"Sezai","year":"2016","journal-title":"J Atr Fibrillation"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0017","doi-asserted-by":"crossref","first-page":"225","DOI":"10.9738\/INTSURG-D-14-00139.1","article-title":"Results of surgery in general surgical patients receiving warfarin: retrospective analysis of 61 patients","volume":"100","author":"Belli","year":"2015","journal-title":"Int Surg"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0018","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0019","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"for the Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0020","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.111.060061","article-title":"Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation","volume":"126","author":"Lane","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0021","series-title":"Pradaxa (dabigatran etexilate) [package insert]","year":"2020"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0022","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/hrt.2005.071183","article-title":"Thrombosis of prosthetic valves: diagnosis and therapeutic considerations","volume":"93","author":"Roudaut","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0023","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/archinte.167.13.1414","article-title":"Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action","volume":"167","author":"Wysowski","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0024","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/ehjcvp\/pvw031","article-title":"A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants","volume":"3","author":"Halvorsen","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.clinthera.2021.04.009_bib0025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/JCN.0b013e3181b152d7","article-title":"Factors associated with long hospital length of stay in patients receiving warfarin after cardiac surgery","volume":"24","author":"Cwynar","year":"2009","journal-title":"J Cardiovasc Nurs"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:49Z","timestamp":1758963289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821002034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0149291821002034"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.04.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Prescribing Practices and Outcomes Using Direct-acting Oral Anticoagulants After Cardiac Surgery","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}